BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 37270289)

  • 1. Long-term treatment with teduglutide: a 48-week open-label single-center clinical trial in children with short bowel syndrome.
    Lambe C; Talbotec C; Kapel N; Barbot-Trystram L; Brabant S; Nader EA; Pigneur B; Payen E; Goulet O
    Am J Clin Nutr; 2023 Jun; 117(6):1152-1163. PubMed ID: 37270289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes from a 12-Week, Open-Label, Multicenter Clinical Trial of Teduglutide in Pediatric Short Bowel Syndrome.
    Carter BA; Cohran VC; Cole CR; Corkins MR; Dimmitt RA; Duggan C; Hill S; Horslen S; Lim JD; Mercer DF; Merritt RJ; Nichol PF; Sigurdsson L; Teitelbaum DH; Thompson J; Vanderpool C; Vaughan JF; Li B; Youssef NN; Venick RS; Kocoshis SA
    J Pediatr; 2017 Feb; 181():102-111.e5. PubMed ID: 27855998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Variable Response to Teduglutide in Pediatric Short Bowel Syndrome: A Single Country Real-Life Experience.
    Guz-Mark A; Hino B; Berkowitz D; Hartman C; Millman PN; Orlanski-Meyer E; Shaoul R; Spector-Cohen I; Weiss B; Zangen T; Shamir R
    J Pediatr Gastroenterol Nutr; 2022 Sep; 75(3):293-298. PubMed ID: 35730756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variation of plasma citrulline as a predictive factor for weaning off long-term parenteral nutrition in children with neonatal short bowel syndrome.
    Proli F; Faragalli A; Talbotec C; Bucci A; Zemrani B; Chardot C; Abi Nader E; Goulet O; Lambe C
    Clin Nutr; 2021 Aug; 40(8):4941-4947. PubMed ID: 34358840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome.
    Jeppesen PB; Gilroy R; Pertkiewicz M; Allard JP; Messing B; O'Keefe SJ
    Gut; 2011 Jul; 60(7):902-14. PubMed ID: 21317170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Citrulline correlations in short bowel syndrome-intestinal failure by patient stratification: Analysis of 24 weeks of teduglutide treatment from a randomized controlled study.
    Jeppesen PB; Gabe SM; Seidner DL; Lee HM; Olivier C
    Clin Nutr; 2020 Aug; 39(8):2479-2486. PubMed ID: 31784300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Therapy With Teduglutide in Parenteral Support-Dependent Patients With Short Bowel Syndrome: A Case Series.
    Ukleja A; To C; Alvarez A; Lara LF
    JPEN J Parenter Enteral Nutr; 2018 May; 42(4):821-825. PubMed ID: 29603279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors Associated With Response to Teduglutide in Patients With Short-Bowel Syndrome and Intestinal Failure.
    Jeppesen PB; Gabe SM; Seidner DL; Lee HM; Olivier C
    Gastroenterology; 2018 Mar; 154(4):874-885. PubMed ID: 29174926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of teduglutide after 52 weeks of treatment in patients with short bowel intestinal failure.
    O'Keefe SJ; Jeppesen PB; Gilroy R; Pertkiewicz M; Allard JP; Messing B
    Clin Gastroenterol Hepatol; 2013 Jul; 11(7):815-23.e1-3. PubMed ID: 23333663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Teduglutide (Gattex) in Patients With Crohn's Disease and Need for Parenteral Support Due to Short Bowel Syndrome-associated Intestinal Failure.
    Kochar B; Long MD; Shelton E; Young L; Farraye FA; Yajnik V; Herfarth H
    J Clin Gastroenterol; 2017 Jul; 51(6):508-511. PubMed ID: 27433811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacologic options for intestinal rehabilitation in patients with short bowel syndrome.
    Jeppesen PB
    JPEN J Parenter Enteral Nutr; 2014 May; 38(1 Suppl):45S-52S. PubMed ID: 24615689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term results of teduglutide treatment for chronic intestinal failure - Insights from a national, multi-centric patient home-care service program.
    Greif S; Maasberg S; Wehkamp J; Fusco S; Zopf Y; Herrmann HJ; Lamprecht G; Jacob T; Schiefke I; von Websky MW; Büttner J; Blüthner E; Tacke F; Pape UF
    Clin Nutr ESPEN; 2022 Oct; 51():222-230. PubMed ID: 36184208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-Center Experience with the Use of Teduglutide in Adult Patients with Short Bowel Syndrome.
    Lam K; Schwartz L; Batisti J; Iyer KR
    JPEN J Parenter Enteral Nutr; 2018 Jan; 42(1):225-230. PubMed ID: 29505151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Teduglutide on Diarrhea in Pediatric Patients with Short Bowel Syndrome-Associated Intestinal Failure.
    Fifi A; Raphael BP; Terreri B; Uddin S; Kaufman SS
    J Pediatr Gastroenterol Nutr; 2023 Nov; 77(5):666-671. PubMed ID: 37889619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Independence From Parenteral Nutrition and Intravenous Fluid Support During Treatment With Teduglutide Among Patients With Intestinal Failure Associated With Short Bowel Syndrome.
    Iyer KR; Kunecki M; Boullata JI; Fujioka K; Joly F; Gabe S; Pape UF; Schneider SM; Virgili Casas MN; Ziegler TR; Li B; Youssef NN; Jeppesen PB
    JPEN J Parenter Enteral Nutr; 2017 Aug; 41(6):946-951. PubMed ID: 27875291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide--analyses from a randomised, placebo-controlled study.
    Jeppesen PB; Pertkiewicz M; Forbes A; Pironi L; Gabe SM; Joly F; Messing B; Loth S; Youssef NN; Heinze H; Berghöfer P
    Clin Nutr; 2013 Oct; 32(5):713-21. PubMed ID: 23587733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure.
    Jeppesen PB; Pertkiewicz M; Messing B; Iyer K; Seidner DL; O'keefe SJ; Forbes A; Heinze H; Joelsson B
    Gastroenterology; 2012 Dec; 143(6):1473-1481.e3. PubMed ID: 22982184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experience with teduglutide treatment for short bowel syndrome in clinical practice.
    Pevny S; Maasberg S; Rieger A; Karber M; Blüthner E; Knappe-Drzikova B; Thurmann D; Büttner J; Weylandt KH; Wiedenmann B; Müller VA; Bläker H; Pascher A; Pape UF
    Clin Nutr; 2019 Aug; 38(4):1745-1755. PubMed ID: 30145039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The colon as an energy salvage organ for children with short bowel syndrome.
    Norsa L; Lambe C; Abi Abboud S; Barbot-Trystram L; Ferrari A; Talbotec C; Kapel N; Pigneur B; Goulet O
    Am J Clin Nutr; 2019 Apr; 109(4):1112-1118. PubMed ID: 30924493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Efficacy of Teduglutide in Pediatric Patients With Intestinal Failure due to Short Bowel Syndrome: A 24-Week, Phase III Study.
    Kocoshis SA; Merritt RJ; Hill S; Protheroe S; Carter BA; Horslen S; Hu S; Kaufman SS; Mercer DF; Pakarinen MP; Venick RS; Wales PW; Grimm AA
    JPEN J Parenter Enteral Nutr; 2020 May; 44(4):621-631. PubMed ID: 31495952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.